Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. (ENLV) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
enlv · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Enlivex Therapeutics Ltd.You ENLV | $18M | N/A | — | — |
 CollPlant Biotechnologies Ltd. CLGN | $5M | N/A | — | -$0.94 |
 Cadrenal Therapeutics, Inc. Common Stock CVKD | $12M | N/A | — | -$6.64 |
 CytoMed Therapeutics Limited GDTC | $13M | N/A | — | -$0.34 |
 Lisata Therapeutics, Inc. LSTA | $31M | N/A | — | -$1.91 |
 MetaVia Inc. MTVA | $4M | N/A | — | -$7.35 |
 NuCana plc NCNA | $13M | N/A | — | -$7.94 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Enlivex Therapeutics Ltd. (ENLV) measures how much investors pay for each dollar of the company's trailing earnings. ENLV's current PE ratio of N/A is calculated by dividing its stock price of $0.74 by its TTM earnings per share of —.
Frequently asked questions
ENLV pe ratio · 6 questionsENLV's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.74 and TTM EPS of —. Data sourced from Financial Modeling Prep via ENLV's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Enlivex Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09